Novartis' cancer drug Gleevec, Roche Holding's flu drug Tamiflu, and Biogen Idec and Elan's multiple sclerosis drug Tysabri are on a list of drugs under safety investigation by the FDA. The agency said being on the quarterly list "does not mean that FDA has identified a causal relationship between the drug and the listed risk."

Full Story:

Related Summaries